Gene-editing firms form patent alliance against Editas, Broad
By Max Stendahl,
Boston Business Journal
| 12. 16. 2016
Four biotechs involved in the burgeoning field of gene editing announced a formal patent alliance on Friday that puts them at odds with two Cambridge institutions doing the same, Editas Medicine and The Broad Institute.
The four companies — Berkeley, California-based Caribou Biosciences, ERS Genomics of Ireland, and Cambridge-based firms CRISPR Therapeutics (Nasdaq: CRSP) and Intellia Therapeutics (Nasdaq: NTLA) — all licensed or sublicensed intellectual property regarding CRISPR/Cas9 gene-editing from the same source: biologist Emmanuelle Charpentier, the Regents of the University of California and the University of Vienna.
On the other side of the dispute is Editas (Nasdaq: EDIT), which has been using CRISPR technology developed by Feng Zhang of the Broad Institute.
Charpentier and Zhang have each received patents for CRISPR/Cas9, a method of cutting out and replacing part of a gene that has the potential to revolutionize the treatment of serious genetic disorders. Their backers — UC Berkeley and the Broad, respectively — are currently duking it out in a court case in Virginia before the U.S. Patent and Trademark Office. A decision is expected in coming...
Related Articles
By Pallab Gosh and Gwyndaf Hughes, BBC News | 06.26.2025
Work has begun on a controversial project to create the building blocks of human life from scratch, in what is believed to be a world first.
The research has been taboo until now because of concerns it could lead to...
By Rhys Blakely, The Times | 06.24.2025
Scientists have created fertile mice from male genetic material alone, a breakthrough that could one day open the door to human babies who inherit their genes from two fathers.
The experiment, led by Professor Yanchang Wei at Shanghai Jiao Tong...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Gina Kolata, The New York Times | 06.20.2025
A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of type 1 diabetes. One year later, these 10 patients no longer need insulin. The other two patients need...
